Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CRISPR THERAPEUTICS AG

(CRSP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Social Buzz: Gamestop, Other Wallstreetbets Stocks Edge Higher, See Few New Additions

04/12/2021 | 06:41am EDT


© MT Newswires 2021
All news about CRISPR THERAPEUTICS AG
05/07CRISPR THERAPEUTICS  : Nkarta to Co-Develop Gene-Edited Cell Therapies for Cance..
MT
05/06CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-..
GL
04/29CRISPR THERAPEUTICS  : to Participate in Upcoming Investor Conferences
AQ
04/28CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2..
GL
04/27CRISPR THERAPEUTICS  : Q1 Net Loss Widens Amid Revenue Surge
MT
04/27CRISPR THERAPEUTICS  : Management's Discussion and Analysis of Financial Conditi..
AQ
04/27CRISPR THERAPEUTICS AG  : Results of Operations and Financial Condition, Financi..
AQ
04/27CRISPR THERAPEUTICS  : Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 R..
MT
04/27CRISPR THERAPEUTICS  : Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q1 Los..
MT
04/27CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 F..
GL
More news
Financials (USD)
Sales 2021 365 M - -
Net income 2021 10,5 M - -
Net cash 2021 2 318 M - -
P/E ratio 2021 -115x
Yield 2021 -
Capitalization 8 160 M 8 160 M -
EV / Sales 2021 16,0x
EV / Sales 2022 99,5x
Nbr of Employees 410
Free-Float 84,4%
Chart CRISPR THERAPEUTICS AG
Duration : Period :
CRISPR Therapeutics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRISPR THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 160,50 $
Last Close Price 101,46 $
Spread / Highest target 117%
Spread / Average Target 58,2%
Spread / Lowest Target -55,6%
EPS Revisions
Managers and Directors
NameTitle
Samarth Kulkarni Chief Executive Officer & Director
Rodger Novak Chairman & President
Michael John Tomsicek CFO & Principal Accounting Officer
Tony W. Ho Executive VP, Head-Research & Development
Stephen R. Kennedy Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
CRISPR THERAPEUTICS AG-29.66%8 160
MODERNA, INC.56.17%65 346
LONZA GROUP AG1.51%47 533
IQVIA HOLDINGS INC.30.82%44 923
CELLTRION, INC.-25.77%32 687
SEAGEN INC.-20.36%25 314